1. Home
  2. EXTR vs MIRM Comparison

EXTR vs MIRM Comparison

Compare EXTR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Extreme Networks Inc.

EXTR

Extreme Networks Inc.

HOLD

Current Price

$16.91

Market Cap

2.3B

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$79.64

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXTR
MIRM
Founded
1996
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
3.4B
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
EXTR
MIRM
Price
$16.91
$79.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
11
Target Price
$21.80
$92.45
AVG Volume (30 Days)
1.2M
790.7K
Earning Date
01-28-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$1,181,108,000.00
$471,794,000.00
Revenue This Year
$12.45
$53.78
Revenue Next Year
$7.33
$19.91
P/E Ratio
$282.29
N/A
Revenue Growth
14.31
53.66
52 Week Low
$10.10
$36.88
52 Week High
$22.89
$79.95

Technical Indicators

Market Signals
Indicator
EXTR
MIRM
Relative Strength Index (RSI) 41.28 69.86
Support Level $16.57 $63.23
Resistance Level $17.29 $66.77
Average True Range (ATR) 0.46 3.33
MACD -0.01 0.90
Stochastic Oscillator 18.94 98.15

Price Performance

Historical Comparison
EXTR
MIRM

About EXTR Extreme Networks Inc.

Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: